Exploring Biomarkers in Age Stratified PUMCH Dementia Cohort

Status Recruiting

Clinical Trial Summary

Biomarkers are important for early and precise diagnosis of dementia. However, the causes of dementia in different age are different. We designed an age stratified dementia cohort and tried to explore biomarkers of different groups of dementia, incorporating neuropsychology, multi-model neuroimaging, metabolics and proteomics based fluid biomarkers as well as genetic biomarkers. Autopsy after clinical follow up help to verify the biomarkers.

Clinical Trial Description

Baseline data collection and cohort establishing: Detailed clinical information including demographic data, clinical history, past history and physical examination are collected. Formatted neuropsychological battery is used in all patients, including screening tests (MMSE, MoCA-PUMCH, ADL, HAD) and domain specific evaluation (Memory, executive function, visual spatial, calculation, language). Samples including serum, CSF, urine, skin, saliva are stored. Every patient is followed up every 6 months. Autopsy brain tissue will be collected if patients died. Multi-model neuroimaging evaluation: Structure and functional brain 3T-MRI; 7T-MRI； PET-CT including FDG, Aβ（18F-AV45）,tau（18F-THK5317, 18F-T807）; EEG Multi-omics biomarkers research: CSF AD biomarkers (Aβ40,42, ptau181, ttau, NfL, Neurogranin), comparison of different methods, including ELISA, Electrochemical, Mass Spectroscopy. The standardization of CSF biomarkers analysis in China. Exploring new fluid biomarkers: CSF and Urine proteomics; CSF and serum glycomics and metabolomics. To explore new biomarkers in differentiation of different causes of dementia, age onset and prognosis of dementia. Genetic biomarkers evaluation: including pathogenic gene mutation panel examination and WES. Data analysis and biomarkers evaluation: Dementia patients are stratified based on age onset, cause of dementia, cognition severity, effect of therapy, prognosis. Identify multi-omics biomarkers in different groups. Comparing the relationships between biomarkers and clinical presentations as well as neuroimaging. Autopsy based accurate diagnosis help further defining biomarkers. Acquiring stratified biomarkers with high sensitivity and specificity. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04924361
Study type	Observational
Source	Peking Union Medical College Hospital
Contact	Chenhui Mao, Doctor
Phone	+86018611895308
Email	maochenhui@pumch.cn
Status	Recruiting
Phase
Start date	December 1, 2020
Completion date	November 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05686486` - Gentle Gymnastics and Relationship Between Family Caregivers and Residents With Dementia in Nursing Homes	N/A
Terminated	`NCT05451693` - Outreach-ER: A Dementia Care Intervention Program
Recruiting	`NCT05820919` - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase	N/A
Enrolling by invitation	`NCT06040294` - Dementia and Disability Simulation for College Nursing Students' Senior Activity Facilitation Skills	N/A
Completed	`NCT05114187` - An Internet-Based Education Program for Care Partners of People Living With Dementia	N/A
Recruiting	`NCT06322121` - Vascular Aspects in Dementia: Part 2
Active, not recruiting	`NCT03676881` - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Completed	`NCT04426838` - Cognitive Behavioral Therapy for Insomnia for the Dementia Caregiving Dyad	N/A
Recruiting	`NCT03462485` - Pilot Study of the Effects of Playing Golf on People With Dementia	N/A
Active, not recruiting	`NCT03677284` - Managing Time With Dementia: Effects of Time Assistive Products in People With Dementia	N/A
Completed	`NCT03849937` - Changing Talk Online (CHATO) Study	N/A
Recruiting	`NCT06284213` - Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
Recruiting	`NCT05579236` - Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
Completed	`NCT05080777` - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems	N/A
Completed	`NCT04571697` - A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
Completed	`NCT03583879` - Using Gait Robotics to Improve Symptoms of Parkinson's Disease	N/A
Recruiting	`NCT06033066` - Financial Incentives and Recruitment to the APT Webstudy	N/A
Active, not recruiting	`NCT05204940` - Longitudinal Observational Biomarker Study
Recruiting	`NCT05684783` - Dementia Champions in Homecare
Completed	`NCT03147222` - Function Focused Care: Fracture Care at Home	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.